Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 1:36 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 4,291 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Gastro-Intestinal Cancer Clear all

Conditions: Breast Cancer, Metastatic Gastric Cancer, Esophageal Cancer
Interventions: Paclitaxel; Drug
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Colorectal Cancer, Colorectal Neoplasms, Colorectal Carcinoma, Colorectal Tumors, Neoplasms, Colorectal
Interventions: NUC-3373 + leucovorin, NUC-3373, NUFOX, NUFOX + VEGF pathway inhibitor, NUFOX + EGFR inhibitor, NUFIRI, NUFIRI + VEGF pathway inhibitor, NUFIRI + EGFR inhibitor, NUC-3373 + bevacizumab; Drug
Lead sponsor: NuCana plc; Other
Eligibility: 18 Years and older
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 6
States / cities: Boston, Massachusetts • Durham, North Carolina • Nashville, Tennessee + 2 more

Conditions: Advanced Solid Malignancies, Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC)
Interventions: BMS-986523, Gemcitabine, Nab-Paclitaxel, Cetuximab, Pembrolizumab; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 4
States / cities: Baltimore, Maryland • San Antonio, Texas • West Valley City, Utah + 1 more

Conditions: HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2 Positive Solid Tumors, HER2 Amplification, Colorectal Cancer
Interventions: ELVN-002, Trastuzumab, 5-Fluorouracil, Oxaliplatin, Capecitabine, Eribulin, paclitaxel, Leucovorin; Drug
Lead sponsor: Enliven Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 275 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 3
States / cities: Plantation, Florida • St Louis, Missouri • Fairfax, Virginia

Conditions: Colorectal Cancer, Rectal Cancer
Interventions: SignateraTM assay; Genetic
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Anal Cancer, HIV Infection, Human Papilloma Virus Infection
Interventions: comparison of screening methods, laboratory biomarker analysis, questionnaire administration, quality-of-life assessment; Procedure · Other
Lead sponsor: AIDS Malignancy Consortium; Network
Eligibility: 18 Years and older · Female only
Enrollment: 276 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 11
States / cities: Los Angeles, California • San Francisco, California • Chicago, Illinois + 6 more

Conditions: Advanced Solid Tumor, Non Small Cell Lung Cancer, Pancreatic Carcinoma, Colorectal Cancer
Interventions: CLSP-5282; Drug
Lead sponsor: Clasp Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 4
States / cities: Durham, North Carolina • Philadelphia, Pennsylvania • Nashville, Tennessee + 1 more

Conditions: Advanced Solid Tumours, Non-Small Cell Lung Cancer (NSCLC), Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer (CRC)
Interventions: AZD0022, Cetuximab; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 3
States / cities: Duarte, California • New York, New York • Fairfax, Virginia

Conditions: Cancer, Severe Major Depression, Schizophrenia, Bipolar Disorder, Lung Cancer, Breast Cancer, Head and Neck Cancer, Gastrointestinal Cancer
Interventions: Proactive Psychiatry Consultation (PPC), Enhanced Usual Care (EUC); Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 185 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Kidney Cancer, Head and Neck Cancer, Breast Cancer, Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Ovarian Cancer, Esophageal Cancer, Gliomas
Interventions: 177Lu-J591; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Cancer Weight Loss
Interventions: TCMCB07, Placebo; Drug
Lead sponsor: Endevica Bio; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 25
States / cities: Tucson, Arizona • Los Angeles, California • Santa Monica, California + 22 more

Conditions: Colorectal Cancer, Metastatic Cancer
Interventions: positron emission tomography, radiofrequency ablation; Procedure
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Esophageal Cancer
Interventions: Radiation Therapy, Surgery, Tissue Sample; Procedure
Lead sponsor: Nasser Hanna, M.D.; Other
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 7
States / cities: Galesburg, Illinois • Indianapolis, Indiana • Terre Haute, Indiana + 2 more

Conditions: Colorectal Cancer
Interventions: trastuzumab, fluorouracil, leucovorin calcium, oxaliplatin; Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2003
U.S. locations: 47
States / cities: Birmingham, Alabama • La Jolla, California • San Francisco, California + 29 more

Conditions: Metastatic Colorectal Cancer
Interventions: Volrustomig, FOLFIRI (Fluorouracil (5-FU), leucovorin, irinotecan), Bevacizumab; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 10
States / cities: Scottsdale, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 7 more

Conditions: Rectal Cancer, Colon Cancer, Crohn's Disease, Polyp, Procidentia, Diverticulitis
Interventions: PINPOINT Endoscopic Fluorescence Imaging System; Device
Lead sponsor: Novadaq Technologies ULC, now a part of Stryker; Industry
Eligibility: 18 Years and older
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 11
States / cities: Los Angeles, California • Orange, California • San Diego, California + 7 more

Conditions: Cutaneous Melanoma, Non-small Cell Lung Cancer, Colorectal Neoplasms, Pancreatic Neoplasms, Mesothelioma
Interventions: PF-08046049; Drug
Lead sponsor: Seagen, a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 27
States / cities: Los Angeles, California • Pasadena, California • San Francisco, California + 11 more

Conditions: Colorectal Cancer
Interventions: qualitative interviews; Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Colorectal Cancer
Interventions: Temozolomide + Olaparib; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Colorectal Cancer, Colorectal Carcinoma, Colorectal Tumor
Interventions: enzastaurin, irinotecan, cetuximab; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 20
States / cities: Casa Grande, Arizona • Tucson, Arizona • Los Angeles, California + 17 more

Conditions: Colorectal Cancer, Bladder Cancer
Interventions: Telehealth Intervention, Standard of care; Behavioral · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Duarte, California

Conditions: Low Anterior Resection, Proctosigmoid Resection, Rectal Cancer
Interventions: Covidien Radial Reload Stapler with Tri-Staple Technology; Device
Lead sponsor: Medtronic - MITG; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 3
States / cities: Tampa, Florida • Durham, North Carolina • Spokane, Washington

Conditions: Metastatic Colorectal Cancer
Interventions: FOLFOX + bevacizumab, Vitamin D; Drug · Dietary Supplement
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 18
States / cities: Boise, Idaho • Fruitland, Idaho • Meridian, Idaho + 13 more

Conditions: Venous Thromboembolism, Thoracic Surgery, Esophageal Cancer
Interventions: Not listed
Lead sponsor: McMaster University; Other
Eligibility: 18 Years and older
Enrollment: 187 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 3
States / cities: Ann Arbor, Michigan • Rochester, Minnesota • Cleveland, Ohio

Search by objective public record fields.

Pharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With Cancer

A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment

A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies

ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer

Circulating Tumor DNA to Monitor the Efficacy of Total Neoadjuvant Therapy for Rectal Cancer

Anal HPV Tests in Screening for Cell Changes in the Anus in Patients With HIV

A Study of CLSP 5282 in HLA-A*03:01 Positive Adult Patients With Solid Tumors (SENTINEL-101)

A Phase I/IIa Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD0022 as Monotherapy and in Combination With Anti-cancer Agents in Adult Participants With Tumours Harbouring a KRASG12D Mutation

Bridge: Proactive Psychiatry Consultation and Case Management for Patients With Cancer

177Lu-J591 Antibody in Patients With Nonprostate Metastatic Solid Tumors

Safely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pancreatic Ductal Adenocarcinoma (PDAC) Undergoing Chemotherapy

Fludeoxyglucose F 18-PET Imaging for Early Detection of Residual Disease in Patients Undergoing Radiofrequency Ablation of Liver Metastases From Colorectal Cancer

Cetuximab and Radiation Therapy for Surgically Resectable Esophageal and Gastroesophageal (GE) Junction Carcinomas

Combination Chemotherapy Plus Trastuzumab in Treating Patients With Advanced, Recurrent, or Metastatic Colorectal Cancer

A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer

Perfusion Assessment in Laparoscopic Left Anterior Resection

A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors

The Patient-Perspective of Complications After Colon and Rectum Surgery: A Qualitative Analysis

TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer

A Study of Irinotecan Plus Cetuximab With or Without Enzastaurin in Participants With Colorectal Cancer

Telehealth Intervention for Ostomy Self-Management

Radial Reload Open LAR Case Series

Study of Vitamin D in Untreated Metastatic Colorectal Cancer

Incidence of Venous Thromboembolism in Patients Undergoing Major Esophageal Resection